Crinetics Pharmaceuticals is the lead sponsor of 7 current clinical trials in our USA, UK and EU (CTIS) registers. 5 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Atumelnant. The most-studied condition is Congenital Adrenal Hyperplasia.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841 · Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Drug: Atumelnant |
Phase 2/3 | Recruiting | 2026-01 | UK, USA |
|
An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia
NCT06712823 · ClinicalTrials.gov ↗ · Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Drug: Atumelnant |
Phase 2 | Recruiting | 2025-02 | UK, USA |
|
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163 · ClinicalTrials.gov ↗ · Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Drug: Atumelnant |
Phase 3 | Recruiting | 2025-12 | UK, USA |
|
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054 · ClinicalTrials.gov ↗ · Carcinoid Syndrome, Carcinoid, Carcinoid Tumor
|
Phase 3 | Recruiting | 2025-11 | UK, USA |
|
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252 · ClinicalTrials.gov ↗ · SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
|
Phase 1/2 | Recruiting | 2025-11 | USA |
|
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
NCT05804669 · ClinicalTrials.gov ↗ · Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
Drug: Atumelnant |
Phase 1/2 | Active, closed | 2023-10 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Crinetics Pharmaceuticals as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
2025-521672-60-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Ongoing | Spain, France, Germany + 1 more |
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 6 | 5 |
| Clinical trials in UK | 4 | 4 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Neurocrine Biosciences | 2 |
| H. Lundbeck | 1 |
Sponsors with the most current trials registered for this condition.
Crinetics Pharmaceuticals is the lead sponsor of 6 current trials on ClinicalTrials.gov in our USA and UK registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 1 drug or biological as interventions. The most frequent are Atumelnant (4). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.